Abstract
Biologic treatments have modified the therapeutic armamentarium in the treatment of many dermatological and non- dermatological diseases and data on literature have widely focused on the efficacy and safety of TNF-alpha inhibitors in psoriasis.
Although the etiopathogenesis has not completely elucidated, inflammation appears the lait motif unifying the immune-pathogenesis of diverse skin disease, as atopic dermatitis, alopecia areata and hidradenitis suppurativa.
Actually, data on the off-label use of biologics in cutaneous immune-mediated inflammatory diseases are scarce and restricted to anecdotal cases and case series.
The present review aims to evidence the major off- label use of TNF-alpha inhibitors in dermatology.
Keywords: Inflammation, immuno-mediated disease, anti-TNF-alpha, off-label use.
Current Drug Safety
Title:Biologic Therapy in Inflammatory and Immunomediated Skin Diseases: Safety Profile
Volume: 11 Issue: 1
Author(s): Giulia Ganzetti, Anna Campanati, E. Molinelli and A. Offidani
Affiliation:
Keywords: Inflammation, immuno-mediated disease, anti-TNF-alpha, off-label use.
Abstract: Biologic treatments have modified the therapeutic armamentarium in the treatment of many dermatological and non- dermatological diseases and data on literature have widely focused on the efficacy and safety of TNF-alpha inhibitors in psoriasis.
Although the etiopathogenesis has not completely elucidated, inflammation appears the lait motif unifying the immune-pathogenesis of diverse skin disease, as atopic dermatitis, alopecia areata and hidradenitis suppurativa.
Actually, data on the off-label use of biologics in cutaneous immune-mediated inflammatory diseases are scarce and restricted to anecdotal cases and case series.
The present review aims to evidence the major off- label use of TNF-alpha inhibitors in dermatology.
Export Options
About this article
Cite this article as:
Ganzetti Giulia, Campanati Anna, Molinelli E. and Offidani A., Biologic Therapy in Inflammatory and Immunomediated Skin Diseases: Safety Profile, Current Drug Safety 2016; 11 (1) . https://dx.doi.org/10.2174/1574886310666151014121732
DOI https://dx.doi.org/10.2174/1574886310666151014121732 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting Tumor Necrosis Factor Alpha for Alzheimer’s Disease
Current Alzheimer Research Use of Analogs of Peptide Hormones Conjugated to Cytotoxic Radicals for Chemotherapy Targeted to Receptors on Tumors
Current Drug Delivery Molecular and Cellular Regulators of Cancer Angiogenesis
Current Cancer Drug Targets Recurrent Hepatitis C After Liver Transplantation
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Familial Non-Syndromic Clear Cell Renal Cell Carcinoma
Current Molecular Medicine New and Highly Potent Antitumor Natural Products from Marine-Derived Fungi: Covering the Period from 2003 to 2012
Current Topics in Medicinal Chemistry Human ABC Transporters at blood-CNS Interfaces as Determinants of CNS Drug Penetration
Current Pharmaceutical Design The Anti-tumor Activity and Mechanisms of rLj-RGD3 on Human Laryngeal Squamous Carcinoma Hep2 Cells
Anti-Cancer Agents in Medicinal Chemistry Chemistry and Biology of Curacin A
Current Pharmaceutical Design Gene Expression Profiling and its Practice in Drug Development
Current Genomics Encountering and Advancing Through Antiangiogenesis Therapy for Gliomas
Current Pharmaceutical Design Incorporation of Anti-angiogenic Therapies in the Treatment of Epithelial Ovarian Cancer: Current Perspectives and Future Directions
Current Angiogenesis (Discontinued) Pharmacological Properties and Therapeutic Potential of Naringenin: A Citrus Flavonoid of Pharmaceutical Promise
Current Pharmaceutical Design Ghrelin and Growth Hormone Secretagogues, Physiological and Pharmacological Aspect
Current Drug Discovery Technologies Enhanced Pro-Apoptotic Effect of Tetrandrine Loaded Nanoparticles Against Osteosarcoma Cells
Current Drug Delivery Acetylation Control of Cancer Cell Metabolism
Current Pharmaceutical Design The Role of Prostaglandins in Liver Ischemia-Reperfusion Injury
Current Pharmaceutical Design The Role of Stromal Components in Pancreatic Cancer Progression
Anti-Cancer Agents in Medicinal Chemistry Recent Advances in the Diagnosis and Therapy of Primary Adrenal Insufficiency
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Genito-Urological Cancers in Elderly Patients
Anti-Cancer Agents in Medicinal Chemistry